Alberta Cancer Foundation in partnership with Arnie Charbonneau Research Institute invites researchers to submit their applications for a new funding opportunity for research focused on sarcoma and/or pancreatic cancer.
As the official fundraising partner for all 17 cancer centres in Alberta, including the Cross Cancer Institute in Edmonton and the Tom Baker Cancer Centre in Calgary, we are uniquely positioned to accelerate breakthroughs and bring results to patients faster.
We do not exist to raise money. We raise money as a means to an end. We ignite cancer research through the support of our donors. We invest your dollars with a clear line of sight to patient outcomes. Our strategy is to invest in initiatives that provide real-life returns. We measure the return on investment in results, outcomes and impact.
Clinicians, healthcare professionals, researchers, patients and families help us determine those priorities. We then “source” initiatives and programs that align with them. These will be specific investments made in transformative opportunities, foundational infrastructure, and innovations leading to improved patient outcomes due to better clinical practice and care.
The Alberta Cancer Foundation is partnering with two other organizations for an exciting new investment opportunity. The Cancer Detection Challenge is led by Alberta Innovates, and sponsored by Alberta Cancer Foundation and DynaLIFE Medical Labs. We are inviting members of the Alberta cancer technology, research and clinical communities to identify and support the development of technology to detect and diagnose cancer earlier, improving outcomes for Alberta patients with cancer.
Working in partnership with CancerControl Alberta, the Alberta Cancer Foundation’s Building Excellence Program provides annual support for professional development and educational opportunities to Alberta Health Services healthcare professionals in the area of cancer care. The Building Excellence Program is designed to support opportunities that will enable healthcare professionals to enhance patient experience to world class levels at the cancer centres throughout Alberta.
The Foundation is seeking to invest in solutions that improve outcomes for Albertans facing all cancer types through earlier detection, diagnosis and risk stratification of patients. Of particular interest are opportunities using liquid biopsies and biomarkers for the earlier detection of cancer in patients. A liquid biopsy examines a sample of blood and looks for circulating biomarkers from a tumor or for pieces of DNA from tumor cells. A liquid biopsy may be used to help find cancer at an early stage, before a patient displays any symptoms. Investments must have a direct line of sight to patients and families and a clear and direct impact on patient outcomes.
Every day, 53 Albertans hear the words, “you have cancer.” The Alberta Caner Foundation aims to improve the lives of Albertans touched by cancer.
The Alberta Cancer Foundation is pleased to announce the availability of the 2020 Sartore Multidisciplinary Summer Studentship in Palliative and Supportive Care in Oncology to the top ranked applicant in the area of Clinical Nutrition, Medicine, Nursing, Occupational Therapy, Physical Therapy, Social Work, Pharmacy, Respiratory Therapy or other relevant professions based at the Cross Cancer Institute in Edmonton.
For additional information, please contact Program Investment at programinvestment@albertacancer.ca or by phone at 403 476 2423.
At the Alberta Cancer Foundation, we are focused on changing the lives of Albertans facing cancer. Every day, we make the most impactful improvements to cancer care in Alberta. Together, we are bringing earlier detection, improved treatments, enhanced quality of life, and prevention strategies to all Albertans so that no matter where Albertans hear the words “you have cancer”, the investments we make today will change their lives.
We are delighted to announce the first call for the R. K. Dixon Family Award in Hematologic Oncology Research. This Program has been established on behalf of Mr. Robert (Rob) Dixon through a philanthropic gift under the estate of Kathleen M. Dixon, the widow of Mr. Dixon. Faced with a diagnosis of Hodgkin’s-Lymphoma in his early 40s, Mr. Dixon turned his personal cancer journey into remarkable dedication towards advancing cancer research and education in Alberta. As the Chairman of Project Alpha and in hopes of achieving a cancer-free future, Bob led the Alberta Cancer Foundation’s first-ever capital campaign – marking the beginning of new approaches to leveraging philanthropic support for cancer research in Alberta. Recognized widely throughout Calgary for his mantra of “attitude is everything” – and fueled with positivity no matter the circumstances – he lived each day to its fullest.
The Foundation is inviting members of the Alberta cancer research and clinical community to submit specific research proposals in the area of Hematologic Oncology based at the Tom Baker Cancer Centre. We are seeking to invest in solutions that improve outcomes for Albertans facing cancer related to hematology through earlier detection, diagnosis, treatment and improved quality of life.
Individuals must be led by a Team Lead based at the Tom Baker Cancer Centre however, the team may include members from around the globe focused on making a significant impact in hematological cancer research and education. The research proposal must have a direct line of sight to patients and families and a clear and direct impact on patient outcomes.
Researchers interested in submitting a proposal must register by 12:00 PM (MST) on November 30, 2018 and submit their proposals by 12:00 PM (MST) January 21, 2019.
Further information is available in the Expression of Interest FAQ
The Alberta Cancer Foundation is delighted to announce the first call for the Award in Hematological Cancer Research in memory of Dr. Rachel Mandel.
Dr. Rachel Mandel faced her cancer with determination and passion while living every moment of her life. It is the privilege of her friends and family, together with the Alberta Cancer Foundation, to continue her mission and do what is possible to enable future patients to survive. The Dr. Rachel Mandel Lymphoma and Blood Cancers Research Fund is an enduring memorial on indomitable spirit.
“On May 25, 2015, I was diagnosed with Diffuse Large B-Call Non-Hodgkin’s Lymphoma. I am truly amazed at what only a year has done to challenge me in every way possible and for me to come out stronger and to find myself more than ever before.” – Dr. Rachel Mandel
At the Alberta Cancer Foundation, we are focused on changing the lives of Albertans facing cancer. Every day, we make the most impactful improvements to cancer care in Alberta. Together, we are bringing earlier detection, improved treatments, enhanced quality of life, and prevention strategies to all Albertans so that no matter where Albertans hear the words “you have cancer”, the investments we make today will change their lives.
The Foundation invited members of the Alberta cancer research and clinical community to submit specific research proposals in the area of hematological cancers based at the Cross Cancer Institute or the University of Alberta. We are seeking to invest in solutions that improve outcomes for Albertans facing cancer related to hematology through earlier detection, diagnosis, treatment and improved quality of life.
Proposals must be led by a Team Lead based at either the University of Alberta or the Cross Cancer Institute however, may include a geographically spread team that is required to make a significant impact in hematological cancer research and education. The research proposal must have a direct line of sight to patients and families and a clear and direct impact on hematological cancer patient outcomes in Alberta.
We looked for applications from teams across multiple disciplines, including medicine, nursing, physics, engineering, psychology, etc. Highly qualified individuals ideally holding an academic appointment at the University of Alberta or with Alberta Health Services at the Cross Cancer Institute and with an interest in hematology oncology.
We were particularly interested in opportunities that will impact patients with lymphoma, multiple myeloma and hematological pediatric cancers.
Further information is available in the Frequently Asked Questions